论文部分内容阅读
目的:探讨格列奎酮治疗2型糖尿病的药代动力学与动态血糖等多项目指标临床相关性。方法:近年诊断2型糖尿病患者22名,应用美国动态血糖监测系统(CGMS Mini Med Inc),测量药物治疗后不间断连续血糖监测曲线,与本药药代动力学水平作一动态分析。结果:1)口服本药2.5h时血糖水平曲线最低平,与其它时段血糖水平曲线有统计学差异(P<0.001)。2)其中每日6Am口服本药2.5h时血糖水平曲线为24h最低平,与其它时段血糖水平曲线有统计学差异(P<0.001)。3)口服本药7.5h后血糖水平曲线渐次升高,至直再次口服本药后血糖水平曲线渐次降低至直口服本药2.5h时血糖水平曲线最低平。4)每日服药一次24h血糖水平曲线较不服药者血糖水平曲线明显低平(P<0.001)。结论:每日6Am口服本药为最佳服药时间,口服本药2.5h时降糖作用最强,本药可在体内维持7.5-24h。
Objective: To investigate the clinical correlation between the pharmacokinetics of gliclazide in treatment of type 2 diabetes mellitus and dynamic multi-index of blood glucose. Methods: Twenty-two type 2 diabetic patients were diagnosed in recent years. CGMS Mini Med Inc was used to measure the continuous blood glucose monitoring curve after drug treatment. The pharmacokinetic level of this drug was dynamically analyzed. Results: 1) The blood glucose level curve was the lowest at 2.5h after oral administration, and the blood glucose level curve at other time was statistically different (P <0.001). 2) The daily blood glucose level of 6Am at 2.5m daily was the lowest at 24 hours, and the blood glucose level at other times was statistically different (P <0.001). 3) After oral administration of 7.5h blood glucose level curve gradually increased to straight again after oral administration of the drug gradually decreased blood glucose level curve until the oral 2.5h when the blood glucose level curve flattest. 4) once a day medication blood glucose level curve was significantly lower than the curve of blood glucose levels were significantly lower (P <0.001). Conclusion: 6Am daily oral administration of the drug is the best time to take this 2.5h oral hypoglycemic effect of the strongest, the drug can be maintained in vivo 7.5-24h.